Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...

Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash ...

The leading life sciences reagents and instruments company is expected to announce its fiscal second-quarter earnings for ...

Shares of Bio-Techne Corp. TECH slipped 2.90% to $58.51 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.07% to 6,827.41 and ...

Shares of Bio-Techne Corp. TECH shed 2.13% to $57.44 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.24% to 6,800.26 and Dow ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Ousted Venezuelan President Nicolás Maduro pleaded not guilty to narcotrafficking charges during his arraignment in U.S. federal court Monday, defiantly telling a judge that he was still the head of ...

On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion. "Immediately upon close, this ...

Biotech called the shots in the Bay Area’s year-end capital scramble, with the single largest sale in the region clocking in ...

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical ...